Metformin (generic), Glucophage News

"We continue to develop INVOKANA for the treatment of type 2 diabetes, and are pleased to share the latest results at the upcoming ADA meeting," said , M.D., Ph.D., Vice President of Cardiovascular/Metabolism Clinical Development at Janssen.

Today, the U.S. Court of Appeals for the Federal Circuit partially affirmed a 2011 District Court decision, with a 2-1 ruling that a claim in a Novo Nordisk patent related to the use of repaglinide in combination with metformin for the treatment of type 2 diabetes was invalid.

Main Category: Women's Health / Gynecology Also Included In: Obesity / Weight Loss / Fitness ; Fertility ; Diabetes Article Date: 19 Jun 2013 - 2:00 PDT Women with polycystic ovary syndrome, or PCOS, lost significantly more weight when they took two drugs that are traditionally used to treat diabetes , rather than either drug alone, a study from ... (more)

MannKind Corporation recently completed a phase III study on its diabetes candidate Afrezza.

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that NESINA and the fixed-dose combination therapies KAZANO and OSENI are now available by prescription in pharmacies in the United States .

June 3, 2013 - UT Southwestern Medical Center researchers are seeking 150 adults with type 2 diabetes to take part in the local arm of a major national clinical trial that will compare benefits and side effects of four widely used therapies to lower blood-sugar levels.

Memorial Veterans Administration Hospital, will describe the results of Elcelyx's Phase 2a clinical trial that compared NewMet with generic metformin in patients with Type 2 diabetes.

Women with polycystic ovary syndrome, or PCOS, lost significantly more weight when they took two drugs that are traditionally used to treat diabetes, rather than either drug alone, a study from Slovenia demonstrates.

Memorial Veterans Administration Hospital, will describe the results of Elcelyx's Phase 2a clinical trial that compared NewMet with generic metformin in patients with Type 2 diabetes.

Intarcia Therapeutics, Inc. today announced its support for the American Diabetes Association's call for larger, longer-term, and more rigorous datasets and an independent review of pooled data on the safety of incretin-based diabetes medications, including GLP-1 analogs and DDP-4 inhibitors.

Metformin does not reduce the occurrence of gestational diabetes among pregnant women with polycystic ovarian syndrome treated with metformin throughout pregnancy, according to a small study published in the June issue of Diabetes Care .

The motives behind a new algorithm for diabetes treatment by the American Association of Clinical Endocrinologists have been called into question by a respected clinician in a New York Times opinion piece.

Boehringer Ingelheim and Eli Lilly and Company are pleased to announce that the companies' diabetes alliance will have a strong scientific and clinical presence at the 73rd American Diabetes Association Scientific Sessions in Chicago, 2125 June, with 34 posters, abstracts and an oral presentation.

Medicare Part D beneficiaries are two to three times more likely than those covered by the U.S. Department of Veterans Affairs to be prescribed brand name diabetes drugs rather than generics, a new study suggests.

Indiana University School of Medicine is studying the effects of three drugs on fighting diabetes and is looking for people to test them.

Manufacturer's dossier did not contain suitable data for any therapeutic indication Dapagliflozin has been approved in Germany since November 2012 for the treatment of type 2 diabetes mellitus.

Dr. Sidney M. Wolfe M.D ., the editor of Public Citizen's Worst Pills, Best Pills warns that there can be dangerous interactions for people with both Type 1 and Type 2 Diabetes who use oral diabetes medications.

The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study is a pragmatic clinical trial that will compare the long-term effects of diabetes medications on glucose-lowering efficacy and patient-centered outcomes, according to a report published online May 20 in Diabetes Care .

GlaxoSmithKline [NYSE: GSK] confirmed today that a joint advisory committee to the U.S. Food and Drug Administration voted to continue to make Avandia available to appropriate patients with the majority of the members voting to either modify or remove the Risk Evaluation and Mitigation Strategy program in place.

In adults with type 2 diabetes not adequately controlled with metformin, lixisenatide once daily offers diabetes control similar to that of exenatide twice daily, with some added benefits, according to a study published online May 22 in Diabetes Care .